

- ment. *Am J Med* 1993;94:313-328.
10. Boyce JM. Methicillin-resistant *Staphylococcus aureus* in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. *Infect Control Hosp Epidemiol* 1992;13:725-737.
 11. Boyce JM, White RL, Spruill EY. Impact of methicillin-resistant *Staphylococcus aureus* on the incidence of nosocomial staphylococcal infections. *J Infect Dis* 1983;148:763.
 12. Turnidge J, Lawson P, Munro R, Benn R. A National survey of antimicrobial resistance in *Staphylococcus aureus* in Australian teaching hospitals. *Med J Aust* 1989;150:65-72.
 13. French GL, Cheng AFB, Ling JML, MO P, Donnan S. Hong-Kong strains of methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* have similar virulence. *J Hosp Infect* 1990;15:117-125.
 14. Levy CE, Montelli AC, Furtado JS, Pereira AA, Mamizuka EM, Silva MLR, et al. Resistência a drogas em cepas bacterianas de pacientes de serviços hospitalares: laboratório de referência do sistema COBA. *Revista de Microbiologia de São Paulo* 1991;22:21-27.
 15. Correa FJB, Hultze RRU, Rodrigues E, Higaki Y, Silva GA, Malik AM. Distribuição percentual de germes isolados de infecções hospitalares em 24 hospitais do Estado de São Paulo. In: Conferencia Nacional em Controle de Infecções, São Paulo, setembro de 1991. *Programa*. São Paulo: Associação Paulista de Estudos e Controle de Infecção Hospitalar; 1991:30,31 (Resumo).
 16. Lewis E, Saravolatz LD. Comparison of methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* bacteremia. *Am J Infect Control* 1985;13:109-114.
 17. McManus AT, Mason AD, McManus WF, Fruitt BA Jr. What's in a name? Is methicillin-resistant *Staphylococcus aureus* just another *S aureus* when treated with vancomycin? *Arch Surg* 1989;124:1456-1459.
 18. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AL, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101:1644-1655.
 19. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1989. *Am J Infect Control* 1988;16:128-140.
 20. Geerdes HF, Ziegler D, Lode H, Hund M, Loerr A, Fangmann W, et al. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. *Clin Infect Dis* 1992;15:991-1002.
 21. McCabe WR, Jackson GG. Gram-negative bacteremia: II, clinical, laboratory, and therapeutic observations. *Arch Intern Med* 1962;110:856-864.
 22. Hinshaw L, Peduzzi P, Young E, Sprung C, Shatney C, Sheagren J, et al. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. *N Engl J Med* 1987;317:659-665.
 23. Watanakunakorn C. Bacteremic *Staphylococcus aureus* pneumonia. *Scand J Infect Dis* 1987;19:623-627.
 24. Quarles LD, Rutsky EA, Rostand SG. *Staphylococcus aureus* bacteremia in patients on chronic hemodialysis. *Am J Kidney Dis* 1985;6:412-419.
 25. Horan TC, White JW, Jarvis WR, et al. Nosocomial infection surveillance, 1984. *MMWR* 1986;35:17-29.
 26. Aube H, Milan C, Blettery B. Risk factors for septic shock in the early management of bacteremia. *Am J Med* 1992;93:283-288.
 27. Bihari DJ. Septicaemia: the clinical diagnosis. *J Antimicrob Chemother* 1990;25(suppl C):1-7.
 28. Hershov RC, Khair WF, Smith NL. A comparison of clinical virulence of nosocomial acquired methicillin infection in a university hospital. *Infect Control Hosp Epidemiol* 1992;13:587-593.
 29. Romero-Vivas, Rubio M, Fernandez C, Picazo J. Mortality associated with nosocomial bacteremia due to methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 1995;21:1417-1423.
 30. Sader HS, Pignatari ACC, Hollis RJ, Jones RN. Evaluation of interhospital spread of methicillin-resistant *Staphylococcus aureus* in São Paulo Brazil, using pulsed-field electrophoresis of chromosomal DNA. *Infect Control Hosp Epidemiol* 1994;15:320-323.

MDR TB Trends in US

Gina Pugliese, RN, MS
Martin S. Favero, PhD

In CDC's 1991 and 1992 first-quarter surveys of tuberculosis (TB) drug susceptibility, TB was found to be resistant to at least isoniazid (INH) in 9.1% and 9.6%, respectively. Multidrug-resistant (MDR) TB; resistant to both INH and rifampin) was found in 3.5% of all case-patients in 1991 and 1992.

The CDC recently reported the results from the first 4 years, 1993 through 1996, of national surveillance of drug resistance among all reported TB case-patients in the United States. Overall resistance to at least INH was 8.4%; rifampin, 3.0%; both INH and rifampin (MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and

ethambutol hydrochloride, 2.2%. Rates of resistance were significantly higher for case patients with a prior TB episode.

Among those without prior TB, INH resistance of 4% or more was found in 41 states, New York City, and the District of Columbia. A total of 1,457 MDR TB cases were reported from 41 states, New York City, and the District of Columbia; 38% were reported from New York City. Rates of INH and streptomycin resistance were higher for cases among US-born compared with foreign-born patients, but rates of rifampin resistance and MDR TB were similar. Among US-born patients, resistance to first-line drugs, particularly rifampin mono-resistance, was significantly higher among those with HIV

infection.

The CDC concluded that, compared with the US surveys in 1991 and 1992, INH resistance has remained relatively stable. In addition, the percentage of MDR TB has decreased, although the national trend was influenced significantly by the marked decrease in New York City. Foreign-born and HIV-positive patients and those with prior TB infection have higher rates of resistance. The widespread extent of INH resistance confirms the need for drug susceptibility testing to guide optimal treatment of patients with culture-positive disease.

FROM: Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States. *JAMA* 1997;278:833-837.